From Stockhouse today,
Roger;
This is the kick...
A CDN$2.25 billion market per year for the GAS vaccine alone, potentially--
THIS DOESN'T INCLUDE THE VOLUNTARY ADULT MARKET, OR
POTENTIAL GROWTH OF THIS MARKET INTO THE FUTURE!! I haven't told
you that yet-- I've been conservative!!
The odds of a vaccine like this getting to market are probably greater than 50-50,
as I've noted.
This is called up-side indeed!! IDB is currently valued at just CDN$100 million--
and has an opportunity with a CDN$3.5 billion per year, or more, market, all
things considered!! What would YOU pay for a greater than 50% chance at a
CDN$3.5 billion monopoly?? Just CDN$100 million????? Your paying less than
that right now, by holding IDB!! But IDB's value is now being increasingly
recognized by smart, or early, money!! With the first human trial results out on
GAS, and senior analyst backing, and the potential re-surrgence of biotech, which
has had a long rest, IDB could be HUGGGGE!!!
But also, there is significant down-side 'protection'. Again IDB is currently valued
at only CDN$100. With a pipeline of products now to be expected off an FDA
approved diagnostic technology(ie. Velogene), there is significant down-side
protection. Remember that this platform has a market potential in excess of
CDN$750 million, and IDB is trading at just CDN$100 million. This system can
diagnose certain diseases up to a day earlier than current diagnostics. **The
saving of just one day*, by allowing for a days faster diagnosis, and more
appropriate treatment faster, can save up to, or more than, CDN$1000, per patient
in hospital time, treatment costs, ect.. It can also save lives!! This is a compelling
opportunity. What a diversification of risk at these prices!! What is this
opportunity alone worth!!
-So, just a CDN$100 million value for IDB currently.
-A greater than 50% chance at a CDN$3.5 billion, per year, monopoly.
-An FDA approved diagnostic system with a market in excess of CDN$750
million.
And also the rest that is IDB:
-An AIDS vaccine re-entering phase I/II clinicals.
-A TB vaccine partnered to one of the largest vaccine houses.
-An E. Coli vaccine.
-An increasingly proven ability to find and develop leading edge technologies.
This could mean many, many, more opportunities in the years to come.
-Also with Mitsubishi, Sybron, and the US Department of Defence, working on
newer diagnostic tests using IDB technology.
-With analyst recognition, and with institutional shareholder recognition, and
perhaps substantially more media coverage also-- especially given the scope of
IDB's mission.
Only CDN$100 million, for this company!!!!!!
C'mon!!!
Not for long!!!!!!
It looks like the PAYDAY is very shortly Roger!!
Anyone new to IDB, your welcomed to have a look at the following report:
geocities.com
Over 5,775 visits.
Be Wise,
Sir_Holler |
